Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new Medium article from the Department of Physiology, Anatomy and Genetics chronicles Gero Miesenböck's seminal research into optogenetics, starting at his eureka moment some 20 years ago.

None © Gero Miesenböck

On the afternoon of 12 June 1999, a Saturday, Gero Miesenböck returned to his apartment in Manhattan from a long walk after lunch, ready to open a book he had been absorbed in, Independence Day by Richard Ford. “As I was reaching for the book, drifting from the real world into Ford’s fictional New Jersey, there was the idea of optogenetic control. I knew instantly that I was on to something. My wife remembers my excitement as I tried to explain the concept to her, and especially the terrible hangover nearly two years later when my postdoc and I celebrated that we had got it to work.”

That Manhattan moment launched a series of now classical studies that made Miesenböck the first scientist to modify nerve cells genetically so that their activity could be controlled by light. This breakthrough technology, called optogenetics, has transformed neuroscientific research and opened new possibilities for the treatment of brain disorders. By providing the means to control neural signals with high precision, optogenetics has raised neurobiology’s standards of proof. It has shed light, literally and figuratively, on virtually every brain function: sensation and movement, motivation and learning, sleep and waking, communication and decision-making.

Read more (Medium website)

Similar stories

Regular meat consumption linked with a wide range of common diseases

Research

Regular meat consumption is associated with a range of diseases that researchers had not previously considered, according to a large, population-level study conducted by a team at the University of Oxford.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.